Innovations in Drug Development

A recent publication in Nature highlights an exciting breakthrough in drug delivery a needle-free insulin system that works through the skin. Researchers developed a smart, depth-responsive polymer that overcomes the long-standing challenge of transdermal insulin delivery by adapting to the skin environment and enabling efficient transport across biological barriers. The results showed effective and sustained blood glucose control in preclinical models without signs of inflammation, pointing toward a future of painless and non-invasive diabetes management. What I find particularly interesting is how this concept of stimuli-responsive polymer systems can be extended beyond insulin delivery. In areas like wound healing and urinary tract infections (UTIs), where biofilms and tissue barriers limit treatment efficacy, such smart delivery platforms could play a transformative role. Designing systems that respond to local environments (like pH or infection signals) to deliver antibiotics, nanoparticles, or even phage therapy could significantly improve targeted treatment outcomes. This kind of interdisciplinary approach combining material science with biomedical applications opens up exciting possibilities for developing next-generation therapeutic strategies. Looking forward to exploring how these concepts can be adapted to tackle real-world clinical challenges. Source: https://lnkd.in/g7JksnSX #Biotechnology #DrugDelivery #Nanomedicine #PhageTherapy #WoundHealing #UTI #Innovation

Gold Diggers of Pharma: Turning Abandoned Drugs into Blockbusters In the shadows of pharmaceutical R&D lies a quiet revolution. A new breed of biotech startups—Pharma’s Gold Diggers—are mining failed, forgotten, or shelved drugs and turning them into clinical and commercial successes. Why Drugs Fail (Yet Still Hold Value) Not all failures are final. Many drugs stumble in trials due to: * Narrow misses on clinical endpoints * Side effects in limited populations * Lack of commercial fit for Big Pharma * Being ahead of their time Startups now scout these “scrap heap” molecules, reviving them at a fraction of original R&D costs—and often in a fifth of the time. Meet the Drug Resurrectors 1. Ignota Labs – AI-Powered Resurrection
Uses AI to identify why Phase 2/3 drugs failed (e.g., liver toxicity), tweaks the chemistry, and revives them.
Highlight: A PDE9 inhibitor for Alzheimer’s, backed by $6.9M in seed funding. “We don’t start from zero. We start from almost there.” 2. Cycle Pharmaceuticals – Formulation Wizards
Transforms delivery formats (e.g., injectable to inhalable), eliminates cold chains, and redirects drugs to rare diseases.
Example: Reformulated glatiramer acetate for cystic fibrosis. “Formulation is our innovation engine.” 3. Melior Discovery – Phenotypic Pivoters
Screens old drugs on new disease models. Partnered with Pfizer, Merck, and AstraZeneca.
Repositioned an anti-inflammatory for Type 2 diabetes. 4. Recursion Pharmaceuticals – High-Throughput Innovators
Combines AI + cell imaging to screen 1M+ compounds across diseases.
Backed by Bayer & Sanofi. “We’re mapping the druggable universe using data.” 5. Algernon Pharmaceuticals – Rare Pathway Hunters
Repurposes generics for niche conditions.
Example: Ifenprodil, once a neurodrug, now in trials for pulmonary fibrosis and chronic cough. Famous Pharma Revivals * Sildenafil (Pfizer): Failed angina drug → Viagra; now over $2B/year. * Thalidomide (Celgene): Once banned, now approved for multiple myeloma. * Minoxidil (Upjohn): From blood pressure drug to Rogaine for hair growth. * Avastin → Lucentis (Genentech): Cancer biologic → macular degeneration therapy. Signs of the Next Gold Rush Look out for: * Licensing of old Phase II/III assets * Startups with AI repurposing platforms * Announcements of fast-tracked approvals * Novel formulations: sprays, patches, sublinguals, nano-tech Closing Insight
“Every failed drug is a story half-written. These startups are writing its second chapter.” In a high-cost, high-risk R&D world, these companies show that yesterday’s failures may still hold the cures of tomorrow.

🧬 The $2.6 Billion Problem: How Virtual Patients Are Revolutionizing Drug Development Here's a sobering reality: 9 out of 10 drugs fail in clinical trials after billions in investment. Each approved drug costs $2.6 billion and takes over 10 years to develop. This isn't just expensive—it's unsustainable. But AI-powered virtual patients are changing everything. What are virtual patients? Think digital twins of human physiology—sophisticated AI simulations trained on massive datasets of patient records, biological processes, and clinical outcomes. They can predict how drugs will behave in the human body, and even in individual human bodies, before a single person takes them. The game-changing impact:  🎯 Early failure detection - Identify toxicity and efficacy issues before expensive human trials  ⚡ Precision dosing - Test thousands of dosing regimens across diverse populations virtually  🔬 Biomarker discovery - Accelerate identification of which patients will benefit most  💰 Cost reduction - 30-50% savings in preclinical phases alone Beyond cost savings, this is strategic transformation: ▪️ Faster go/no-go decisions in drug discovery ▪️ Better patient stratification for trials ▪️ Reduced ethical concerns around human and animal testing ▪️ Democratized innovation for smaller biotechs The FDA approved virtual patient use in clinical trials in October 2022 and the first drugs leveraging these are making their way through the clinical trial process. Now the FDA and EMA are seeking to do more to incentivize model-informed drug development Model-Informed Drug Development (MIDD), paving regulatory pathways for widespread virtual patient data in submissions. The bottom line: We're moving from reactive risk management to proactive outcome engineering. Virtual patients aren't just accelerating drug development—they're making precision medicine accessible at scale. For patients waiting for life-saving treatments, this can't come fast enough. What's your take on AI simulation in healthcare? Are we ready for this virtual-first future? #AI #Pharma #DrugDevelopment #VirtualPatients #DigitalHealth #Innovation #PrecisionMedicine

Accelerating Drug Discovery with AI-Powered Molecular Design … 💊🧠 The process of discovering new medicines is long, costly, and inefficient. But emerging techniques in artificial intelligence could transform how we search for promising drug candidates. In a recent paper, researchers explore how combining molecular docking simulations with generative deep learning models enables more focused exploration of chemical space to identify compounds that could effectively bind to therapeutic targets. 👉 The Need for Faster, More Directed Drug Discovery Developing a new approved drug takes over 10 years and costs over $1 billion on average. A key challenge is exploring the vast space of possible chemical compounds to find ones that interact favorably with biological targets involved in disease. Advances in AI may help address this by steering search toward fruitful regions. 👉 Molecular Docking Meets Deep Generative Models Molecular docking simulates how drug compounds might bind to target proteins. Deep generative models like GANs and autoencoders can create novel molecular structures. By combining them, the models can invent compounds tailored to fit a target based on docking scores. 👉 How the Research Was Conducted The authors reviewed recent papers on docking-based generative models for drug design. They categorized the approaches based on model types and Molecular docking software used. The also analyzed key evaluation metrics like binding affinity prediction, synthetic accessibility, and chemical diversity. 👉 Key Insights for Next-Generation Drug Discovery The analysis identified critical innovations like using binding pocket features to directly constrain generation, scaffold hopping to expand chemical search space, and latent vector optimization to discover high-affinity candidates. These methods display enhanced performance over previous approaches. 👉 Practical Implications and Applications By concentrating exploration on protein binding sites, these AI techniques allow more efficient and effective drug discovery. Target-based generation additionally enables on-demand compound design tailored to specific therapeutics area like cancer or neurodegenerative disease. 👉 Expanding the Frontiers of AI-Powered Medicine Discovery This research charts an important path toward leveraging AI, especially generative deep learning, to accelerate discovery of novel medicines. Critical future directions include incorporating synthesis planning to ensure generated compounds can be practically produced. Ultimately, advanced computational methods may usher in a new era of data-driven, personalized drug development. This emerging field promises to unlock new treatments for patients by innovating how we create and identify promising drug leads. I look forward to seeing rapid translation of these leading-edge techniques into practical tools that users in biotechnology and pharmaceutical research can apply to find tomorrow's cures faster.

One of the most interesting shifts in pharma R&D right now is the emergence of continuous learning loops between computational models and lab experiments. Strategic investments are reinforcing this direction. A recent example is the $1B collaboration between NVIDIA and Eli Lilly and Company, aimed at building an AI factory for drug discovery, leveraging large-scale models trained on the language of biology and chemistry. At the core of this approach is a tight feedback loop between the wet lab and the dry lab, where experimental results continuously update computational models. Instead of the traditional discovery cycle: Hypothesis → experiment → analysis → new hypothesis AI enables something closer to: Model prediction → experiment → real-time data → updated model → next experiment This continuous loop allows research teams to iterate far more quickly. Industry analyses suggest that embedding AI directly into experimental workflows could reduce discovery timelines by as much as 40% in some cases. For pharma organizations, the implications are significant: • accelerating target validation • prioritizing experiments more effectively • reducing failed experimental cycles The companies that succeed may not simply use AI tools. They will build AI-native discovery systems in which computation and experimentation continuously inform one another. Article: https://lnkd.in/gzXqtj2Y #AI #DrugDiscovery #Pharma #Biotech #PrecisionMedicine#AI #DrugDiscovery #Biotech #PharmaR&D

The recent review in Signal Transduction and Targeted Therapy on peptide-based drug development presents a compelling synthesis of the transformative evolution of peptides as therapeutics, delivery platforms, and vaccines. From the perspective of a computational chemist, this article highlights how advances in molecular design, structural optimization, and conjugation strategies have significantly expanded the druggable landscape. Peptides offer a unique balance being more specific than small molecules while also being penetrative and cost-effective than antibodies. A key takeaway is the integration of structural chemistry with delivery innovations to address intrinsic peptide challenges, such as rapid degradation and low oral bioavailability. The advancements in cell-targeting peptide conjugates, particularly for cancer treatment, demonstrate the power of precise molecular recognition combined with smart linkers and cytotoxic payloads, paving the way for next-generation precision oncology. Additionally, peptide-based vaccines illustrate the shift towards safer, highly defined subunit immunotherapies. Overall, this work showcases a multidisciplinary synergy where computational design, synthetic chemistry, and bioengineering converge to accelerate peptide drug discovery. It outlines an exciting path forward, emphasizing the pivotal role of computational tools in tailoring peptides with enhanced stability, selectivity, and target engagement, ultimately leading to more effective and patient-friendly therapeutics. This represents not just an incremental step but a profound leap toward realizing the full potential of peptide therapeutics in modern medicine. #Peptides #Proteins #DrugDiscovery #Biotech #Pharma #PPI #Research

Traditionally, drug discovery starts at the bench. Today, it’s increasingly starting in the "Real World." By linking large-scale genomic data with Electronic Health Records (EHRs)—like the #UKBiobank—researchers are performing "Human Knockout" studies. They identify individuals who naturally lack a certain gene and see how it affects their health over decades. A Prime Example: The discovery of ANGPTL3 inhibitors. By observing that people with a natural genetic deficiency in this protein had exceptionally low lipid levels and zero heart disease, researchers validated a multi-billion dollar drug target before a single molecule was synthesized in a lab. Why RWE in Discovery matters: 🔹 De-risks Development: Validates targets in humans, not just mice. 🔹 Speed: Identifies the right patient sub-populations for Phase I/II trials. 🔹 Efficiency: Shortens the "Valley of Death" between the lab and the clinic.The future of #DrugDiscovery is data-driven. We aren't just looking for new chemicals; we’re looking for the biological clues patients have been giving us all along. https://lnkd.in/ebWz9_VT #Biotech #Genomics #Bioinformatics #RWD #DrugDiscovery #Innovation

🚀 Advances in Next-Generation Drug Delivery Technologies (Jan–Aug 2025) Drug delivery is often called the “last mile” of drug development—it determines whether a therapy can reach its target effectively and safely. As nucleic acid medicines, mRNA vaccines, gene editing, and cell therapies advance, traditional delivery systems are struggling to keep pace. This makes new delivery platforms the critical bottleneck and opportunity for innovation. 📌 Recent Highlights from 2025: ✨ RNACap (Harvard, Science Translational Medicine) An engineered capsule system enabling the first efficient oral delivery of liquid mRNA nanoparticles. Protected from stomach acid, RNACap showed strong efficacy in colitis models—potentially reshaping how we think about mRNA therapeutics. https://lnkd.in/e3QzTM9D ✨TMAB3/RNA Complex (Yale, Science Translational Medicine) A monoclonal antibody forming stable complexes with RNA for systemic delivery. Achieved 1,500× higher tumor enrichment in preclinical cancer models by exploiting ENT2 transporters. https://lnkd.in/eTzUJZgJ ✨RIDE (Shanghai Jiao Tong Univ. & AstraZeneca, Nature Nanotechnology) A VLP-based CRISPR RNP delivery system enabling neuron-specific editing. Demonstrated therapeutic potential in Huntington’s disease models. https://lnkd.in/e8tqQGMM ✨ENVLPE (Helmholtz Munich, Cell) Engineered VLPs delivering all major RNA-guided editors (CRISPR, base, prime) as RNPs—high efficiency, no DNA integration, strong performance in T cells and retinal disease models. https://lnkd.in/evC5RJ_K ✨ENTER (Nature Biotechnology) Elastin-based nanoparticles (ELP) for efficient cytosolic delivery of proteins, siRNA, mRNA, and editing tools. Overcame LNP liver tropism and viral immunogenicity. https://lnkd.in/eF8_CTcY ✨Dual SORT LNPs (UT Southwestern, Nature Biotechnology) Dual-targeted LNPs delivering base editors simultaneously to liver & lung. Corrected genetic mutations in AATD models with long-lasting edits (32 weeks). https://lnkd.in/ekYvxy-v 🌍 Industry Momentum Global deal activity reflects these breakthroughs: LNPs, exosomes, BBB transporters, oral peptide carriers, and vesicle-based systems are attracting billions in partnerships, licensing, and acquisitions. Delivery platforms are no longer just carriers—they are strategic assets defining therapeutic success. 🔮 Looking Ahead Expect continued innovation in biodegradable LNPs, exosome/vesicle systems, oral biologics, and in vivo CRISPR delivery, alongside active M&A as pharma secures platform leadership. #DrugDelivery #mRNA #GeneTherapy #CellTherapy #Biopharma #Innovation

🧬 For the first time, an AI for drug discovery doesn't just make predictions - it explains WHY. Google DeepMind's new TxGemma system doesn't just say "this molecule might work" - it walks you through its reasoning about molecular structure, potentially unlocking a major bottleneck in AI-powered therapeutic development. The breakthrough? TxGemma combines state-of-the-art prediction accuracy with conversational capabilities that bridge the gap between black-box models and scientists who need to understand what's happening. In benchmarks across 66 therapeutic tasks, TxGemma outperformed specialist models on 50 tasks while requiring substantially less training data. The larger 27B-parameter model achieved up to 30% performance improvements against previous systems for predicting drug properties, interactions, and clinical trial outcomes. What's truly innovative is the agentic version, Agentic-Tx, which orchestrates complex workflows by reasoning about molecules, searching literature, and testing hypotheses. It showed a remarkable 52.3% improvement over previous models on challenging therapeutic reasoning benchmarks. Drug development typically takes 10+ years with 90% failure rates. TxGemma could dramatically improve efficiency by both making better predictions AND explaining them, allowing scientists to interpret, trust, and build upon the AI's insights rather than treating it as a mysterious oracle. What do you think this means for the future of drug discovery? Could explainable AI finally bridge the gap between computational predictions and laboratory validation? Full paper link in the comments! #AIinHealthcare #DrugDiscovery #ExplainableAI #MachineLearning #TherapeuticDevelopment